Comparative Study on Effects of GA Nanoparticles Suspension and Unprocessed GA Solution on Oral Bioavailability, Hepatic Function and Liver Antioxidant Enzymes Activities in Carbon Tetrachloride–Induced Liver Damage Rats

Abstract:

Glycyrrhizic acid (GA), the main component from Radix glycyrrihizae, has a variety of pharmacological actions. In present study, GA nanoparticles suspension was prepared by supercritical anti-solvent (SAS) process and high-press homogenization process, and comparative studies were done on oral bioavailability, hepatic function and liver antioxidative activities in carbon tetrachloride–induced liver damage rats after treated with GA nanosuspension and unprocessed GA solution. Micronized CA under the optimum SAS conditions and CA nanosuspension prepared by high-pressure homogenization with the average particle size of about 80nm were obtained. GA nanoparticles suspension, compared with the unprocessed GA can significantly enhance the oral bioavailability. For carbon tetrachloride–induced liver damage rats, GA nanoparticles suspension can significantly reduce the release of ALTand AST. The plasma ALT and AST levels of GA supplementation were effective in decreasing up to 55 and 78.6 percent of model control group, respectively. For the GA solution group, the plasma ALT and AST levels were in decreasing up to 62.8 and 84.5 percent of model control group, respectively. GA nanosuspension could also significantly reduce plasma MDA and enhance SOD, GSH-Px and CAT activity. The CAT, SOD and GSH-Px activities increased by GA nanosuspension were about 1.31-fold, 1.43-fold and 1.28-fold of the unprocessed GA solution group, respectively. These results indicated that the GA nanoparticles suspension can be absorbed more easily than unprocessed GA after oral administration.

• Periodical: Materials Science Forum (Volume 694)
• Pages: 423-429
• DOI: https://doi.org/10.4028/www.scientific.net/MSF.694.423
• Online since: July 2011
• Authors: Lin Zhang, Wei Wei, Yuan Gang Zu, Lei Yang, Xiu Hua Zhao, Bai Shi Zu
• Keywords: Glycyrrhizic Acid, Hepatic Function, Liver Antioxidant Enzymes Activity, Nanoparticles Suspension, Oral Bioavailability

References

[1] Asl, M. N., & Hosseinzadeh, H., 2008. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytotherapy Research, 22, 709–724.

DOI: 10.1002/ptr.2362

[2] Isbrucker R.A. & Burdock G.A., 2006. Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp. ), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of Gly. Regulatory Toxicology and Pharmacology, 46, 167–192.

DOI: 10.1016/j.yrtph.2006.06.002

[3] Kimura M., Moro T. & Motegi H., 2008. In vivo Gly accelerates liver regeneration and rapidly lowers serum transaminase activities in 70% partially hepatectomized rats. European Journal of Pharmacology, 579, 357–364.

DOI: 10.1016/j.ejphar.2007.10.073

[4] Kurisu S, Inoue I, Kawagoe T, Ishihara M, Shimatani Y, Nakama Y, Maruhashi T, Kagawa E, Dai K, Aokage T, Matsushita J, Ikenaga H. S. Kurisu, I. Inoue, T. Kawagoe, et al., 2008. Clinical profile of patients with symptomatic Gly-induced hypokalemia. Journal of the American Geriatrics Society, 56, 1579–1581.

DOI: 10.1111/j.1532-5415.2008.01781.x

[5] Tsuyoshi Y., Kazuki A., Tadayuki I., Tokiyoshi M., K.W., Tetsuji S., Toshitsugu S. & Hideo I., 2007. Inhibitory effect of glycyrrhizin on lipopolysaccharide and d-galactosamine-induced mouse liver injury European. Journal of Pharmacology, 576, 136-142.

DOI: 10.1016/j.ejphar.2007.08.012

[6] Ram, A., Mabalirajan, U., Das, M., Bhattacharya, I., Dinda, A. K., Gangal, S.V. & Ghosh B., 2006. Glycyrrhizin alleviates experimental allergic asthma in mice. International Immunopharmacology, 6, 1468–1477.

DOI: 10.1016/j.intimp.2006.04.020

[7] Nose M., Ito M., Kamimura K., Shimizu M. & Ogihara Y., 1994. A comparison of the antihepatotoxic activity between glycyrrhizin and glycyrrhetinic acid. Planta Medica, 60, 136–139.

DOI: 10.1055/s-2006-959435

[8] Okamoto T. & Kanda T., 1999. Glycyrrhizin protects mice from concanavalin A-induced hepatitis without affecting cytokine expression. International Journal of Molecular Medicine , 4, 149–152.

DOI: 10.3892/ijmm.4.2.149

[9] Okamoto T., 2000. The protective effect of glycyrrhizin on anti-Fas antibody-induced hepatitis in mice. European Journal of Pharmacology, 387, 229–232.

DOI: 10.1016/s0014-2999(99)00807-9

[10] Kimura, M., Inoue, H., Hirabayashi, K., Natsume, H. & Ogihara, M., 2001. Glycyrrhizin and some analogues induce growth of primary cultured adult rat hepatocytes via epidermal growth factor receptors. European Journal of Pharmacology, 431, 151–161.

DOI: 10.1016/s0014-2999(01)01424-8

[11] Fujisawa, K., Watanabe, H. & Kimata, K., 1973. Therapeutic approach to chronic active hepatitis with glycyrrhizin. Asian Medical Journal, 23, 745-756.

[12] Suzuki, H., Ohta, Y., Takino, T., Fujisawa, K. & Hirayama, C., 1983. Effects of glycyrrhizin on biological tests in patients with chronic hepatitis. A double-blind trial. Asian Medical Journal, 26, 423-438.

[13] Arase, Y., Ikeda, K., Murashima, N., Chayama, K., Tsubota, A., Koida, I., Suzuki, Y., Saitoh, S., Kobayashi, M. & Kumada, H., 1997. The long term efficacy and glycyrrhizin in chronic hepatitis C patients. Cancer, 79, 1494–1500.

DOI: 10.1002/(sici)1097-0142(19970415)79:8<1494::aid-cncr8>3.0.co;2-b

[14] Ikeda, K., Arase, Y., Kobayashi, M., Saitoh, S., Someya, T., Hosokawa, T., Senzaki, H., Akuta, N., Suzuki, Y., Suzuki, F. & Kumada, H., 2006. A long term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Digestive Diseases and Sciences, 51, 603–609.

DOI: 10.1007/s10620-006-3177-0

[15] van Rossum, T.G.J., Vulto, A.G., Hop, W.C. & Schalm, S.W., 2001. Glycyrrhizin induced reduction of ALT in European patients with chronic hepatitis C. The American journal of gastroenterology, 96, 2432–2437.

DOI: 10.1111/j.1572-0241.2001.04049.x

[16] van Rossum, T.G.J., Vulto, A.G., Hop, W.C., Brouwer, J.T., Niesters, H.G. & Schalm, S.W., 1999. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. Journal of Gastroenterology and Hepatology. 14, 1093–1099.

DOI: 10.1046/j.1440-1746.1999.02008.x

[17] Yang X.L., Xu H.B., Wu J.Z. & Xie C.S., 2000. Application of Nano-Technology in the Research of Traditional Chinese Medicine. Journal of Huazhong University of Science and Technology, 28, 104-105.

[18] Reverchon E., De Marco I. & Torino E., 2007. Nanoparticles production by supercritical antisolvent precipitation: A general interpretation. The Journal of Supercritical Fluids, 43, 126-138.

DOI: 10.1016/j.supflu.2007.04.013

[19] Lee L.Y., Wang C.H. & Smith K.A., 2008. Supercritical antisolvent production of biodegradable micro and nanoparticles for controlled delivery of paclitaxel. Journal of Controlled Release, 125, 96-106.

DOI: 10.1016/j.jconrel.2007.10.002

[20] Chattopadhyay P. & Gupta R.B., 2001. Production of griseofulvin nanoparticles using supercritical CO2 antisolvent with enhanced mass transfer. International Journal of Pharmaceutics, 228, 19-31.

DOI: 10.1016/s0378-5173(01)00803-1

[21] Kim M.S., Jin S.J., Kim J.S., Park H.J., Song H.S., Neubert R.H.H. & Hwang S.J., 2008. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. European Journal of Pharmaceutics and Biopharmaceutics, 69, 454-465.

DOI: 10.1016/j.ejpb.2008.01.007

[22] Reverchon E., Della Porta G., Sannino D. & Ciambelli P., 1999. Supercritical antisolvent precipitation of nanoparticles of a zinc oxide precursor. Powder Technology, 102, 127-134.

DOI: 10.1016/s0032-5910(98)00207-1

[23] Park J., Park H. J., Cho W., Cha K. H., Kang Y. S., Hwang S. J., 2010. Preparation and pharmaceutical characterization of amorphous cefdinir using spray-drying and SAS-process. Pharmaceutical Nanotechnology, 396, 239–245.

DOI: 10.1016/j.ijpharm.2010.06.032

[24] Kojima H, Sakurai S, Uemura M, Takekawa T, Morimoto H, Tamagawa Y, Fukui H., 2005. Difference and similarity between non-alcoholic steatohepatitis and alcoholic liver disease. Alcoholism, Clinical and Experimental Research, 29, 259-263.

DOI: 10.1097/01.alc.0000191776.37626.30